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INTRODUCTION 
 Carcinoma of the esophagus is one among the most challenging 
problems confronted by the oncologic surgeon. Esophageal tumors are highly 
likely to result in early mortality owing to the likelihood of advanced disease at 
the time of diagnosis and the challenging nature of their treatment. Survival 
rates have not improved significantly in 25 years despite the availability of new 
treatment modalities.  
 Squamous cell carcinomas are the most common malignancies of the 
esophagus worldwide. However adenocarcinomas of the esophagus and cardia 
are relatively common, particularly is the western hemisphere. The reported 
incidence of these cancers is increasing in the United States at a rate surpassing 
that of any other cancer.  
 This study was undertaken to analyse the incidence and pathological  
pattern of carcinoma of the esophagus at the Government Rajaji Hospital, 
Madurai and to compare that with international literature.  
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AIMS OF THE STUDY 
 
 The aims of this study were to analyze and study  
1. The incidence of carcinoma esophagus age and sex wise.  
2. The clinical presentation of carcinoma esophagus.  
3. The common sites of occurrence.  
4. The pathological pattern of carcinoma esophagus at Government Rajaji 
Hospital, Madurai. 
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REVIEW OF LITERATURE 
ANATOMY OF ESOPHAGUS 
 
 The esophagus commences at the cricopharyngeus muscle at the level of 
the cricoid cartilage and extends 5 to 6 cm in the cervical region to enter the 
thoracic inlet. The intrathoracic esophagus extends an additional 20 to 25 cm to 
the gastro esophageal junction.  
 Typically, many radiologists and surgeons divide the esophagus into 
thirds whereby the upper third extends from the cricopharayngeus to the 
superior portion of the aortic arch, the middle third extends from the aortic arch 
to the inferior pulmonary veins, and the distal third extends from the level of 
the inferior pulmonary veins to the gastro esophageal junction.  
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BLOOD SUPPLY  
 The blood  supply to the esophagus is segmental, with vessels extending 
into the esophagus to form a submucosal vascular plexus. The cervical 
esophagus is supplied primarily by the superior and inferior thyroid arteries, 
whereas the thoracic esophagus is supplied by esophageal arteries arising 
directly from the aorta near the level of carina; the distal esophagus and gastric 
cardia are supplied primarily by the left gastric artery. Venous drainage from 
the esophagus is into the azygous and hemiazygous veins as well as intercostals 
veins that ultimately drain into the azygous system.  
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LYMPHATICS  
 
  The esophagus contains abundant mucosal and submucosal lymphatic 
that communicate with lymphatic channels in the muscular layers to drain either 
directly through the esophageal wall to adjacent lymph nodes or to the thoracic 
duct.  
 
 Lesions in the upper third of the esophagus tend to drain initially to 
internal jugular, cervical, and supraclavicular nodes; in contrast, middle third 
lesions drain initially to paratracheal, hilar, subcarinal, paraesophageal, and 
pericardial nodal regions.  
 
 Distal third tumors tend to drain to nodes along the lesser curvature, left 
gastric artery, and celiac axis. However, because the pattern of lymphatic 
drainage is primarily longitudinal rather than segmental, extensive regional 
dissemination of cancer cells may occur irrespective of the location of the 
primary tumor.     
 
 Celiac nodal metastases have been observed in 10% of patients with 
upper third carcinomas, and nearly 45% of individuals with middle third 
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lesions; approximately 30% patients with middle or lower third carcinomas 
have metastatic disease in deep cervical lymph nodes at presentation.  
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Nerve supply  
Parasympathetic system 
 Vagal system motor and secretomotor  
Sympathetic system: 
 Cervical and upper thoracic ganglion and greater splanchnic nerve.  
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CARCINOMA ESOPHAGUS 
 
PREDISPOSING CONDITIONS  
TYLOSIS  
 Tylosis (focal nonepidermolytic palmoplantar keratoderma) is a rare 
disease inherited in an autosomal dominant manner that is characterized by 
hyperkeratosis of the palms and soles and esophageal papillomas.  
 Patients with this condition exhibit abnormal maturation of squamous 
cells and inflammation within the esophagus and have extremely high risk of 
developing esophageal cancer. The tylosis esophageal cancer (TOC) gene has 
been mapped to 17q25 by linkage analysis of pedigrees associated with high 
risk of esophageal cancer development.  
 
PLUMMER – VINSON / PATERSON – KELLY SYNDROME  
    Plummer-Vinson/Paterson-Kelly syndrome is characterized by iron-
deficiency anemia, glossitis, kelosis, brittle fingernails, splenomegaly and 
esophageal webs. Approximately 10% of individuals with Plummer-
Vinson/Paterson-Kelly syndrome develop hypopharyngeal or esophageal 
epidermoid carcinomas. The mechanisms by which these tumors arise have not 
been fully defined, although nutritional deficiencies as well as chronic mucosal 
irritation from retain food particles at the level of the webs may contribute to 
the pathogenesis of these neoplasms.  
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Caustic Injury  
  Squamous cell carcinomas may arise in lye strictures, often developing 
40 to 50 years following caustic injury. The majority of these cancers are 
located in the middle third of the esophagus. The pathogenesis of these 
neoplasms may be similar to that implicated in esophageal cancers arising in 
patients with Plummer-Vinson syndrome.  
 These cancers are often diagnosed late due to the fact that chronic 
dysphagia and pain due to the lye strictures obscure symptoms of esophageal 
cancer.  
 
Achalasia  
 Achalasia is an idiopathic esophageal motility disorder characterized by 
increased basal pressure in the lower esophageal sphincter, incomplete 
relaxation of this sphincter following deglutition, and aperistalsis of the body of 
the esophagus. A 16 to 30 fold increase in esophageal cancer risk has been 
noted in achalasia patients. These neoplasms typically are squamous cells 
carcinomas, believed to result from prolonged irritation from retained foods at 
the air-fluid interface in the midesophagus. 
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Human papillomavirus infection  
    Several studies suggest that human papillomavirus (HPV) may 
contribute to the pathogenesis of esophageal squamous cell cancers in high 
incidence areas in Asia and South Africa.  
 
Prior Aerodigestive Tract Malignancy  
 Carcinomas of the aerodigestive tract arise as the consequence of 
multistep processes in cancerization fields. Patients with upper aerodigestive 
tract cancers develop second primary cancers at a rare of approximately 4% per 
year. Nearly 10% of secondary neoplasms arising in patients with prior histories 
of oropharyngeal carcinoma arise in the esophagus.  
 
Barrett’s Esophagus  
  Barrett’s esophagus is characterized by the presence of columnar 
epithelium lining 3 or more cm of the distal tubular esophagus in the presence 
or absence of hiatal hernia. Barrett’s esophagus has been associated with a 30 to 
40 fold increase in the risk of adenocarcinoma, the incidence of which 
increased at a rate of 10% per year during the 1980s.  
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MOLECULAR BIOLOGY  
  Flow cytometric and molecular analyses of dysplastic squamous and 
Barrett’s epithelia have revealed that esophageal cancers arise via widespread 
clonal outgrowth of cells exhibiting aberrant cell-cycle regulation. In general, 
genomic instability precedes the appearance of histologic abnormalities in 
esophageal mucosa, and the extent of cell-cycle derangements influences 
progression to malignancy in this setting.  
 Many of the oncogene and tumor suppressor gene mutations frequently 
observed in esophageal cancers and their precursor lesions perturb cell-cycle 
regulation by disrupting the G (1) restriction point.  
 
PATHOLOGY  
   The overwhelming majority of esophageal malignancies may be 
classified as either squamous cell carcinomas or adenocarcinomas. Squamous 
cell carcinomas account for the vast majority of cancers arising in high-
incidence areas throughout the world. Approximately 60% of these neoplasms 
are located in the middle third of the esophagus, whereas 30% and 10% arise in 
the distal third or proximal third of the intrathoracic esophagus, respectively. 
Typically, these tumors are moderately well differentiated and often are 
associated with contiguous or noncontiguous carcinoma in situ, as well as 
widespread submucosal lymphatic dissemination.  
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 Adenocarcinomas frequently arise in the context of Barrett’s esophagus; 
as such, these tumors tend to be localized in the distal third of the esophagus 
and may be fungating or stenotic in appearance. Many of these tumors are well 
differentiated adenocarcinomas, and the vast majority are associated with 
intraepithelial neoplasia. No significant survival differences have been noted in 
adenocarcinoma patients compared with similarly staged individuals with 
squamous cell cancers.  
 Several rare cancers of the esophagus have been described, including 
squamous cell carcinoma with sarcomatous features, as well as adenoid cystic, 
and mucoepidermoid carcinomas. These neoplasms are indistinguishable 
clinically and prognostically from the common types of esophageal carcinomas.    
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CLINICAL PRESENTATION  
 
  Because it lacks a serosal coat, the esophagus is able to distend and 
accommodate considerable intraluminal tumor growth before deglutition is 
affected; as such, 50% of esophageal cancer patients have locally advanced 
unresectable disease or distant metastases at presentation. 
 
 Dysphagia and weight loss are the initial symptoms in approximately 
90% of patients presenting with esophageal cancer. Approximately 75% of the 
esophageal circumference must be involved with tumor before dysphagia is 
experienced; hence, although many patients relate a vague discomfort with 
swallowing for several months, dysphagia to solid foods may progress rapidly 
to total obstruction from circumferential tumor growth. Approximately 20% of 
patients experience odynophagia (painful swallowing). Although the vast 
majority of esophageal cancer patients present with weight loss, cachexia is 
seen in less than 10% of these individuals. Additional presenting symptoms 
may include dull retrosternal pain resulting from invasion of mediastinal 
structures, cough, or hoarseness due to paratracheal nodal or recurrent laryngeal 
nerve involvement. Infrequently, patients may present with pneumonia 
secondary to tracheoesophageal fistula or exsanguinating hemorrhage due to 
erosion of the esophageal neoplasm into the aorta.  
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DIAGNOSIS  
    Esophageal cancer should be suspected in any patient complaining of 
dysphagia and weight loss. A thorough history should be ascertained, focusing 
on preexisting conditions, as well as tobacco and ethanol abuse, which are 
known to be associated with increased esophageal cancer risk.  
 Aspiration cytology should be performed on palpable cervical lymph 
nodes to rule out extrathoracic metastases.  
 
RADIOGRAPHY  
 Chest radiography and barium swallow should be performed; the barium 
swallow provides an inexpensive and important initial assessment of the extent 
of the disease within the esophagus and should include the entire esophagus as 
well as stomach and duodenum; double-contrast studies are preferable because 
they provide more precise evaluation of mucosal patterns and allow detection of 
small lesions that may be missed on single-contrast examination.  
 
ENDOSCOPY  
 Patients who are suspected to have a primary esophageal carcinoma on 
the basis of history, physical examination, or radiographic studies should 
undergo esophagoscopy to establish tissue diagnosis and define the extent of 
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the esophageal lesion. At the time of endoscopy, attention should focus on the 
identification of the neoplasm in relation to cricopharyngeus, the 
squamocolumnar junction, and the diaphragmatic hiatus; in addition the 
presence or absence of satellite lesions, Barrett’s esophagus, and esophagitis 
should be noted. Biopsies and brushings should be obtained from suspicious 
lesions; the combined diagnostic accuracy of these two procedures exceeds 
90%.  
 Vital stains including toluidine blue or lugol’s iodine may be useful to 
guide endoscopic biopsies in situations in which lesions are equivocal. 
Frequently, strictures are encountered that require dilation to allow passage of 
the endoscope and provide temporary relief of dysphagia. Occasionally, the 
esophagus is so structured it cannot be safely dilated; in these situations 
multiple biopsies in four quadrants should be obtained, and the patients treated 
as if they have esophageal carcinoma irrespective of biopsy results. 
Bronchoscopy should always be performed inpatients with potentially 
resectable upper and middle  third esophageal carcinomas to rule out recurrent 
laryngeal nerve involvement and to identify and biopsy suspicious areas within 
the membranous trachea to rule out impending esophagotracheal fistula.   
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CT 
 Once a tissue diagnosis of esophageal cancer has been established, 
additional studies should be obtained to accurately stage the disease according 
to American Joint committee on cancer criteria in order to ascertain prognosis 
and optimize treatment. Tumor length and the degree of obstruction appear to 
have less effect than the extent of wall penetration and lymph node metastases 
in determining survival of esophageal cancer patients. 
 
 Computed tomography (CT) of the test chest and upper abdomen should 
be obtained to evaluate the extent of disease within the chest and rule out 
visceral metastases in the abdomen Current noninvasive imaging modalities are 
imperfect regarding evaluation of local regional disease and detection of distant 
metastases in these individuals. Conventional CT scans detect the primary 
tumor in 75% to 80% of cases; however, sensitivity for local regional nodal 
disease is only 50% to 70%. 
 
 Furthermore, although CT scans may accurately predict respectability in 
as many as 75% of cases, they have not proven useful for assessing response to 
induction therapy in esophageal cancer patients. 
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Endoscopic ultrasound: 
 Endoscopic ultrasonography (EUS) has been advocated as a means to 
enhance the accuracy of staging of esophageal cancers. Several studies indicate 
that in experienced hands, EUS accurately assesses wall involvement in 50% to 
90% of tumors and mediastinal lymph node status in 67% to 100% of patients 
with localized esophageal cancers. EUS may be a valuable noninvasive means 
to detect celiac nodal metastases in esophageal cancer patients sensitivity - 70% 
to 80% and specificity - 88% to 98%). However, the accuracy of EUS is highly 
dependent on the expertise of the unltrasonographer; an incomplete or 
erroneous assessment of lymph node metastases, invasion of adjacent organs, 
and poor staging of early carcinoma have been reported. Furthermore, EUS has 
limited value in staging patients with high – grade obstruction or assessing 
response to induction therapy in esophageal cancer patients.  
 
PET scans: 
 [**18F] Fluorodeoxyglucose (FDG) positron emission tomography 
(PET) scans have been used for staging patients with locally advanced 
esophageal cancers. PET scans may enhance the sensitivity for imaging small 
metastatic deposits in the medastinum and abdomen. Further refinement may 
enable the diagnostic accuracy of PET scans to equal that acheieved by 
minimally invasive staging technique. 
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 Furthermore, preliminary data suggest that PET scans may prove to be 
valuable for assessing response to induction therapy in esophageal cancer 
patients in contrast to CT scans or EUS, which appear to be unreliable for 
evaluation of treatment response in these individuals. Use of these imaging 
modalities may enhance the accuracy of staging in esophageal cancer patients, 
thereby improving stratification of individuals for multimodality treatment 
protocols. 
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STAGING 
  The modern staging of carcinoma of the esophagus is based on the 
tumor/node/metastasis (TNM) classification developed by the American 
Joint Committee on cancer.  
 
 Clearly, patient outcomes depend on the initial stage of the cancer 
at diagnosis. Although surgical pathology yields the most accurate 
staging, the advent of better imaging techniques, including endoscopic 
ultasonography, has improved preclinical staging; (18)F-
flurodeoxyglucose positron emission tomography (FDG-PET) may be 
useful for detection of distant lymphatic and hematogenous metastases.  
 
 At diagnosis, nearly 50% of patients have cancer that extends 
beyond the locoregional confines of the primary. Fewer than 60% of 
patients with locoregional cancer can undergo a curative resection. Nearly 
70% to 80% of resected specimens harbor metastases in the regional 
lymph nodes. Thus, clinicians are often dealing with advanced-stage 
carcinoma in newly diagnosed patients.  
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(American Joint Committee on Cancer (AJCC) TNM Classification 
of Carcinoma of the Esophagus*)         
 
Primary tumor (T) 
 TX Primary tumor cannot be assessed  
 T0 No evidence of primary tumor  
 Tis Carcinoma in situ  
 T1 Tumor invades lamina propria or submucosa  
 T2 Tumor invades muscularis propria   
 T3 Tumor invades adventitia  
 T4 Tumor invades adjacent structures  
 
Regional lymph nodes (N) 
 NX Regional lymph nodes cannot be assessed  
 N0 No regional lymph node metastasis  
 N1 Regional lymph node metastasis  
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Distant metastasis (M) 
 MX Distant metastasis cannot be assessed  
 M0 No distant metastasis  
 M1 Distant metastasis  
 
Tumors of the lower thoracic esophagus  
 M1a metastasis in celiac lymph nodes  
 M1b other distant metastasis  
 
Tumors of the midthoracic esophagus 
 M1a Not applicable  
 M1b nonregional lymph nodes and/or other distant  
 Metastasis  
 
Tumors of the upper thoracic esophagus  
 M1a Metastasis in cervical nodes  
 M1b other distant metastasis  
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Stage Grouping  
 Stage 0  Tis N0 M0 
 Stage I   T1 N0 M0  
 Stage II A  T2 N0 M0  
    T3 N0 M0  
 Stage II B  T1 N1 M0 
    T2 N1 M0 
 Stage III  T3 N1 M0 
    T4 Any N M0  
 Stage IV  Any T Any N1 M1 
 Stage IV A  Any T Any N M1 a 
 Stage IV B  Any T Any N M1 b  
 
Histologic Grade (G)  
 Gx  Grade cannot be assessed  
 G1  Well differentiated 
 G2 Moderately differentiated      
 G3 Poorly differentiated  
 G4  Undifferentiated  
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TREATMENT 
 The treatment of choice for patients with esophageal cancer is 
controversial. Esophagectomy remains the standard of care; however, its 
role has been challenged due to the generally poor outcomes following 
surgical resection alone in patients who typically have locally advanced 
disease. A survey of community care practice patterns between 1988 and 
1993 revealed an increase in the use of chemoradiotherapy relative to 
surgery as primary management of esophageal cancer.  
 
 Currently, in many institutions, primary resection is deferred in 
favour of combined modality therapy with or without adjuvant 
esophagectomy. The routine use of combined modality treatment outside 
the realms of controlled clinical trials is troublesome since most 
randomized trials have not shown a survival advantage of various 
induction regimens compared with esophagectomy alone. Furthermore, 
there is considerable controversy within the surgical literature as to what 
represents the appropriate operation for patients with esophageal cancer; 
the debate focuses primarily on the need for and the extent of lymph node 
dissection during esophagectomy for cancer. The following discussion 
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summarizes the current status of surgery, chemotherapy, radiation therapy 
and combined modality regimens in the treatment of esophageal cancer.  
 
 Primary therapy of esophageal cancer is either surgical or 
nonsurgical. Although the overall results of these approaches are similar, 
the patient populations selected for treatment with each modality are 
usually different, resulting in a potential selection bias against non 
surgical therapy. Patients with poor prognostic features, including those 
with comorbid conditions, or unresectable or metastatic disease, are more 
commonly selected for treatment with nonsurgical therapy.       
 
SURGICAL RESECTION  
Surgical Approaches  
 Various surgical approaches may be used, depending on the size 
and location of the primary tumor and on the preferences of the surgeon. 
The optimal location of the anastomosis has been debated. The 
advantages of the cervical anastomosis include more extensive resection 
of the esophagus, possibility of avoiding thoracotomy, less-severe 
symptoms of reflux, and less severe complications related to anastomotic 
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leak. Advantages of the thoracic anastomosis include a lower incidence of 
anastomotic leak and lower stricture rate.  
 
 Although some surgeons prefer the colon interposition, most 
surgeons use the stomach as the conduit to replace the esophagus after 
esophagogastrectomy. Colon interposition is usually reserved for patients 
who have had previous gastric surgery or other procedures that have 
devascularized the stomach. The use of the gastric conduit simplifies the 
procedure and is associated with equivalent patient satisfaction and fewer 
postoperative complications.  
 
 Several approaches are acceptable for esophagogastrectomy. Ivor-
Lewis esophagogastrectomy uses abdominal and right thoracic incisions, 
with upper thoracic esophagogastric anastomosis (at or above the azygos 
vein). Mobilization of the stomach for use as the conduit is performed, 
with dissection of the celiac and left gastric lymph nodes, division of the 
left gastric artery, and preservation of the gastroepiploic and right gastric 
arteries. This approach may be used for lesions at any thoracic location, 
but margins may be inadequate for tumors in the middle esophagus.  
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 Transhiatal esophagogastrectomy is performed using abdominal 
and left cervical incisions. The mobilization of the stomach for use as the 
conduit is performed as in the Ivor-Lewis esophagogastrectomy. This 
procedure is completed via the abdominal incision, and the gastric conduit 
is drawn through the mediastinum and exteriorized in the cervical incision 
for the esophagogstric anastomosis. This approach may be used for 
lesions at any thoracic location; however, transhiatal dissection of large, 
middle esophageal tumors adjacent to the trachea is difficult and may be 
hazardous. 
Left thoracoabdominal esophagogastrectomy uses a contiguous 
abdominal and left thoracic incision, through the eighth intercostal space. 
Mobilization of the stomach for use as the conduit is performed as 
described previously, and esophagectomy is accomplished via the left 
thoracotomy. Esophagogastric anastomosis is performed in the left chest, 
usually just superior to the inferior pulmonary vein, although it may be 
performed higher if the conduit is tunneled under the aortic arch. This 
approach may be used for lesions in the distal esophagus. 
Minimally invasive esophagectomy might decrease morbidity; 
however, only a few series have been published. Open surgery should 
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remain the standard until studies show the advantages of minimally 
invasive approaches.  
 
Transhiatal Esopagectomy  
Transhiatal esophagectomy entails extirpation of the intrathoracic 
esophagus through the esophageal hiatus of the diaphragm without the 
need for a thoracotomy incision. An upper abdominal incision and a low-
neck incision   are required to isolate the esophagus at either end. The 
organ is next carefully stripped from its mediastinal attachments and 
removed. The prepared esophageal substitute, usually a greater curvature 
gastric tube, is advanced across the esophageal bed in the posterior 
mediastinum, and gastrointestinal continuity is restored by an end-to-side 
esophagogastrostomy in the neck. No attempt is made to perform a   
systematic lymph node dissection apart from the few parahiatal nodes 
removed with the specimen. Occasionally, sampling of readily accessible 
celiac and periesophageal nodes is performed. 
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Standard Transthoracic Esophagectomy 
Transthoracic esophagectomy is probably the most widely 
performed operation for cancer of the esophagus worldwide. The 
procedure carried out through a right or Left thoracotomy incision 
depending on the preference of the surgeon and the location of the tumor 
within the esophagus. Generally, a right thoracotomy is required for 
adequate exposure of tumors in the middle or upper third that are 
anatomically intimately related to the membranous trachea or the arch of 
the aorta.  
 
Tumors located at the gastroesophageal junction or in the lower 
third of the esophagus can be usually approached through a left 
thoracotomy incision. A left sixth interspace incision provides excellent 
exposure of the lower mediastinum, and a semicircular diaphragmatic 
incision performed 1 inch from the costal arch allows access to the upper 
abdomen. The esophagus is mobilized from its mediastinal bed alongwith 
adjoining periesophageal as well as lesser curvature lymph nodes; no 
radical mediastinal or upper abdominal lymphadenectomy is performed. 
Gastrointestinal reconstruction is subsequently achieved by preparation of 
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the esophageal substitute (usually stomach) and advancing it to the neck 
for a cervical anastomosis. Patients operated on through a right 
thoracotomy require a laparotomy to prepare the gastric tube and pass it 
across the posterior mediastinum or retrosternal space for a cervical 
anastomosis. In patients operated on through a left thoracotomy, the 
esophagus is mobilized along its course in the supra aortic posterior 
mediastinum well into the neck. The prepared gastric tube is then passed 
underneath the aortic arch and attached to the esophageal stump. 
Following reattachment of the diaphragm and closure of the thoracotomy, 
a small left cervical incision is performed to retrieve the esophagus and 
the gastric tube. A cervical incision is then performed and the previously 
mobilized esophagus and gastric tube are easily delivered to the neck for a 
cervical anastomosis.  
 
Comparison of Transhiatal and Transthoracic Esophagectomy  
    Several retrospective studies have shown little difference in the 
operative mortality and morbidity between transhiatal and transthoracic 
esophagectomy with limited lymph node dissection.  
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En Bloc Esophagectomy  
   The deep location of the esophagus within the narrow space 
confines of the mediastinum and the lack of a well-defined mesentery 
have generally precluded the application of en bloc resection to patients 
with esophageal carcinoma. The basic principle of operation is extirpation 
of the tumor-bearing esophagus within a wide envelope of adjoining 
tissues that include both pleural surfaces laterally and the pericardium 
anteriorly where these structures are intimately related to the esophagus. 
The lymphatics wedged dorsally between the esophagus and the aorta, 
and the thoracic duct throughout its mediastinal course, are resected en 
bloc with the specimen. This posterior mediastinectomy necessarily 
results in a complete medistinal node dissection from the tracheal 
bifurcation to the esophageal hiatus. Additionally, an upper abdominal 
lymphadenectomy is performed including the common hepatic, celiac, left 
gastric, lesser curvature, parahiatal, and retroperitoneal nodes. The 
purpose of this extended resection is to maximize locoregional control of 
the primary tumor. Critics have argued that the en bloc procedure is 
associated with a high operative mortality and morbidity without an 
apparent survival advantage.  
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Three-Field Lymphadenectomy  
      Three-field lymph node dissection for carcinoma of the esophagus 
has been practiced by Japanese surgeons since the early 1980s. This effort 
was initially promoted by studies showing that the cervical lymph nodes 
were the site of tumor recurrence in 30% to 40% of patients in whom a 
curative resection had been performed. The extended procedure included 
dissection of the cervical, mediastinal, and upper abdominal nodes in 
patients with carcinoma of the thoracic and abdominal esophagus.  
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RADIATION THERAPY  
 It may be used either a external beam irradiation or as intraluminal 
brachytherapy. External beam therapy may be used with a curative intent, 
in the adjuvant, neoadjuvant settings and with concurrent chemotherapy 
as chemoradiation. External beam radiation may also be used as a 
palliative measure in advanced tumors.  
 RT alone should generally be reserved for palliation for patients 
who are medically unable to receive chemotherapy. Alternative radiation 
approaches, such as hypoxic cell sensitizers and hyperfractionation, have 
not resulted in a clear survival advantage. Experience with intraoperative 
radiation as an alternative to external-beam radiation is limited. 
Conformal and intensity modulated RT are currently being investigated. 
In the adjuvant setting, randomized trials do not show a survival 
advantage for preoperative or postoperative RT alone versus surgery 
along for esophageal cancer. This metaanalysis found that neoadjuvant 
chemoradiation and surgery improved 3-year survival and reduced local-
regional cancer recurrence when compared with surgery alone. Such 
analyses only suggest that preoperative approaches need continued 
investigations.  
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Brachytherapy  
         Intraluminal brachytherapy allows the escalation of the dose to the 
primary tumor while protecting the surrounding dose-limiting structures 
such as the lung, heart, and spinal cord. A radioactive source is placed 
intraluminally via endoscope or a nasogastric tube.  
 
 Brachytherapy has been used both as primary therapy (usually as a 
palliative modality), as well as boost following external-beam radiation 
therapy or combined modality therapy. It can be delivered by high dose-
rate or low dose-rate. As a single therapy, brachytherapy is used as a 
palliative modality and results in a local control rate of 25% to 35% and a 
median survival of approximately 5 months.  
 
ENDOLUMINAL PALLIATION TECHNIQUES  
  As previously discussed, surgery remains the standard of care for 
patients with respectable neoplasms; however, many esophageal cancer 
patients are inoperable due to locally advanced or distant metastatic 
disease. Although chemotherapy and radiation therapy are typically used 
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to palliate unresectable disease, many individuals require additional 
measures to relieve dysphagia and pain.  
 Esophageal dilation frequently can alleviate esophageal obstruction 
secondary to malignancy; however, results usually are temporary, and 
patients require repeated treatments. Safe and effective palliation can be 
achieved by endoluminal stents, laser, or photodynamic therapy (PDT) 
techniques.   
 
CHEMOTHERAPY  
 A variety of single agents and combination regimens have been 
evaluated in patients with recurrent or metastatic carcinoma of the 
esophagus. These patients often have a high tumor burden and poor 
performance status with little prospect for prolongation of survival. 
Bleomycin, 5-fluorouracil (5-FU), mitomycin, and cisplatin (CDDP) have 
been used most often because of their single agent activities and their 
additive or synergistic effects with radiation.  
 Chemotherapy can provide transient palliation for some patients 
with advanced locoregional carcinoma, but other approaches (including 
combined modality therapy) are more effective for this purpose.  
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 The list of established chemotherapeutic drugs active against 
esophageal carcinoma is small. In the past 25 years, only 16 cytotoxic 
drugs were investigated systematically against metastatic esophageal 
carcinoma. The activity of nearly all these agents was established against 
squamous cell histology. Cisplatin has been considered one of the most 
active agents, with a single-agent response rate consistently in the range 
of 20% or greater. Older agents considered to be active include 5-FU, 
mitomycin, cisplatin, beomycin, methotrexate, mitoguazone, doxorubicin 
and vindesine. Newer agents that have shown activity include paclitaxel, 
docetaxel, vinorelbine, oxaliplatin with 5-FU, lobaplatin, irinotecan, 
nedaplatin, and gefitinib.  
 
Combination chemotherapy  
     Only in more recent years have combination regimens been 
evaluated in patients with adenocarcinoma. The two-drug combination of 
cisplatin (100 mg/m2 day 1) and 5-FU (1000 mg/m2/d continuous infusion 
for 96 to 120 hours) is the regimen most commonly used to treat patients 
with either squamous or adenocarcinoma histology.  
 Combination chemotherapy for metastatic carcinoma of the 
esophagus continues to evolve. Compared with adenocarcinoma, 
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squamous cell carcinoma appears to be more sensitive to chemotherapy, 
chemoradiation, or radiotherapy; however, the long term outcome is not 
different for patients with the two histologic types. The combination of 5-
FU plus cisplatin is considered an acceptable therapy. It is the most 
investigated and most commonly used regimen for patients with 
carcinoma of the esophagus. Reported response rates to this combination 
vary between 20% and 50%. Paclitaxel combined with 5-FU and cisplatin 
has demonstrated activity in patients with squamous cell carcinoma and 
adenocarcinoma. In addition, the combination of irinotecan (CPT-11) and 
cisplatin appears to have activity, particularly against squamous cell 
carcinoma of the esophagus.  
 Although combination chemotherapy often results in higher 
response rate, it can be associated with higher morbidity.  
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TREATMENT RECOMMENDATIONS AND 
FUTURE DIRECTIONS 
 Although individuals occasionally are diagnosed early due to 
participation in screening protocols, the vast majority of patients with 
esophageal cancer present with either locally advanced (stages IIB or III) or 
inoperable metastatic disease. Esophagectomy remains the standard of care for 
patients who can tolerate resection. Available data from well-designed 
prospective randomized trials do not support the routine use of induction 
chemotherapy in resectable patients.  
 Further more, there are no convincing data that justify the routine use of 
chemotherapy following esophagectomy. Radiation therapy has no proven 
benefit as the sole modality in the induction setting, and current data indicate a 
potential benefit of this treatment modality in patients with positive resection 
margins, but not in completely resected individuals irrespective of nodal status. 
Limited data suggest that combined chemoradiation therapy may be beneficial 
in the induction setting in resectable patients, particularly in individuals 
achieving pathologic complete responses; surgery remains an important 
component of these aggressive protocols since no other modality enables 
accurate assessment of response to induction therapy, and no other intervention 
can enhance local control in this setting. 
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Patients with unresectable cancers should be palliated with chemoradiation 
therapy.  
 
BEST SUPPORTIVE CARE 
 Medically unfit patients or those who develop an unresectable disease 
may be offered brachytherapy, laser therapy, PDT, or any other components of 
best supportive care including esophageal dilatation, pain control, enteral 
feeding and/or therapy to control bleeding. 
 
 For patients with metastatic carcinoma, only palliative care is 
appropriate. Whether to offer best supportive care alone or together with 
chemotherapy should be based on the patient’s performance status. Patients 
with better performance status may be offered best supportive care alone or 
with chemotherapy. 
 
The constituents of best supportive care depend on the patient’s 
symptoms. In the case of esophageal obstruction, the patient may be offered a 
stent placement, laser surgery, PDT, radiotherapy, or a combination of these 
methods, as appropriate. Esophageal dilatation may also be useful.  For patients 
requiring nutritional support, enteral feeding may be warranted. Pain control 
may be achieved with the use of radiotherapy plus pain medications. Similarly, 
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surgery or radiotherapy and / or endoscopic therapy may be indicated in 
patients with brisk bleeding from the carcinoma. 
 
Salvage Therapy 
Salvage therapy can range from aggressive intervention with curative 
intent inpatients with locoreginal relapse to therapy intended strictly for 
palliation in patients for whom cure is not a possibility. For patients with local 
relapse who have not received RT or chemotherapy, RT plus concurrent 
chemotherapy (5-FU/cisplatin) is preferred; other options include endoscopic 
therapies or surgery. For example, re-resection can be considered in selected 
patients with anastomotic recurrences. For patients with anastomotic 
recurrences. For patients who develop a resectable locoregional relapse after 
chemoradiotherapy but have not had surgery, the clinician should determine 
whether the patient is medically fit for surgery and if the relapse is technically 
resectable. If both of these criteria are met, surgery remain an option. If the 
patient has another relapse after surgery, the carcinoma should be considered 
incurable and the patient should receive palliative therapy. Medically unfit 
patients or those who develop an unresectable relapse after chemoradiotherapy 
may be offered brachy therapy, laser therapy, PDT, or any other components of 
best supportive care including esophageal dilatation, pain control, enteral 
feeding, and / or therapy to control bleeding. 
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For patients with metastatic carcinoma, only palliative care is 
appropriate. Whether to offer best supportive care alone or together with 
chemotherapy should be based on the patient’s performance status. Patients 
with a karnofsky performance score of 60 or less should be offered only best 
supportive care. Patients with better performance status may be offered best 
supportive care alone or with chemotherapy. 
Follow-up 
 All patients should be followed systematically. For asymptomatic 
patients, follow-up should include a complete history and physical examination 
every 4 months for 1 year, then every 6 months for 2 years, and annually 
thereafter. A complete blood count, multichannel serum bio-chemical 
evaluation, and a chest radiograph should be obtained as clinically indicated. 
Endoscopy and other radiologic studies should also be considered as clinically 
indicated (eg. Persistent or recurrent dysphagia). In addition, some patients may 
require dilatation of an anastomotic or a chemoradiation – induced stricture. 
OUTCOMES 
 One of the major developments in the surgical therapy of Carcinoma 
esophagus has been the marked improvement in surgical morbidity and 
mortality as a result of improvement in surgical morbidity and mortality as a 
result of improvement in surgical techniques, patient selection and supply 
systems. 
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 Surgical management of patients with Carcinoma esophagus may 
include staging, resection with curative intent and palliative techniques. The 
intent of surgery should be to achieve R0 resection. Palliative surgery should be 
avoided in patients with clearly unresectable or advanced cancer who can be 
effectively palliated with non surgical modalities. 
 The 5 year survival after R0 resection is 15-20% and the median survival 
after R0 resection is approximately 18 months. No difference in survival was 
observed between groups treated with surgery alone or induction therapy 
followed by surgery. 
 Long term outcomes depend on the initial stage of the carcinoma at 
presentation. Stage I, II and III cancer are considered potentially resectable. 
Aggressive preoperative staging (including esophageal ultra sound, PET and 
molecular biologic techniques) may result in improved prognostic stratification, 
improved patient selection for surgical therapy and improved over all survival.  
 Selecting patients for surgery includes assessing whether they are 
medially fit and the extent of their cancer. Patients with advanced comorbidity 
including severe cardiac and pulmonary disease, are not considered for 
resection but may benefit from non invasive palliative intervention. However 
most patients with early stage cancer will tolerate resection. 
 
42 
 
MATERIALS AND METHODS 
 This study consists of 76 cases of Ca esophagus who were admitted at 
Government Rajaji Hospital between November 2007 and November 2009. 
These patients were examined in detail as per the profoma prepared for this 
study. The patients were investigated to confirm the pathological diagnosis and 
to assess the extent and stage of the disease. 
 
 Lower mid third and lower third growths were submitted for surgery 
after respectability was assessed by CT scanning. Of the 24 patients thus 
submitted for surgery only 10 had resectable growths. 8 patients underwent 
Transhiatal esophagectomy and 2 underwent lvor Lewis esophagectomy. 
 
 Post – operatively they were followed up closely until discharge and then 
at weekly intervals for 8 weeks. 
 
 Other patients who had unresectable disease were given external Beam 
Radiotherapy with or without feeding gastrostomy / Jejunostomy. Patients with 
metastatic disease and those with poor performance status were just given 
supportive care. 
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RESULTS OF THE STUDY 
 
Incidence of Ca esophagus was more common in males with a M:F 
incidence ratio of 3.5:1 
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Maximum incidence was in the 6th followed by 5th decades. 
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In the study it was found the maximum incidence in 5th decade for male 
and 6th decade for female. 
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Dysphagia was the most common presenting symptom seen in 94% of 
the patients. Weight loss and anorexia were also common symptoms present in 
70% of the patients other symptoms seen were regurgitation of food in 42%, 
recurrent respiratory infections and pneumonia in 18% of the patients. Cough 
and hoarseness of voice was seen in 12% of patients, odynophagia in 8% and 
gastrointestinal bleed was a rare feature seen in2 % of patients. 
 
Dysphagia 71 94% 
Odynophagia / Pain 6 08% 
Regurgitation 32 42% 
Resp. Infection 13 18% 
GI Bleed 2 2% 
Weight loss / anorexia 53 70% 
Cough and hoarseness 9 12% 
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Though incidence of distal esophageal tumours is increasing worldwide, 
mid third tumours were more common in this study making up to 50% of the 
cases. Lower third tumour were next common making up 33% and upper third 
tumors were least common making up 17% of the total cases. 
 
 
 
Upper 1/3 12 17% 
Mid 1/3 38 50% 
Lower 1/3 26 33% 
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Among the histological types, adenocarcinoma and squamous cell 
Carcinoma were the only 2 types encountered. Despite the increasing incidence 
of adenocarcinoma in the western countries, Squamous cell histology remained 
the predominant type seen in 67(89%) of the patients. Adenocarcinoma was 
seen in only 9 (11%) of the patients. 
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Resectability rate was very poor in our study. Only 8 patients could be 
taken up for Transhiatal esophagectomy and 2 for Ivor Lewis thoracoabdominal 
resections. Majority of the patients (66) had unresectable disease. 
 
Of those with unresectable disease 38 were given palliative external 
beam Radiotherapy withor without Feeding Gastrostomy / Jejunostomy based 
on their level of Dysphagia. 28 patients who had either metastatic disease or 
poor performance status were offered supportive care with pain relief and 
enteral nutrition through’ a feeding gastrostomy / Jejunostomy / Endo luminal 
stenting procedures where appropriate.. 
 
Treatment offered 
A. Surgical resection    10 
1. Transhiatal esophagectomy 8 
2. Ivor Lewis esophagectomy 2 
B. External RT / CT    38 
C. Supportive Care    28 
(FG / FJ / RT Feeding / Pain relief / Endoluminal Procedures) 
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Post op complications  
 On following up the operated patients, complications were 
encountered, which included a mortality rate of 10% which was due to 
anastamotic leak (in a patient post Ivor-lewis oesophagectomy). 
Pulmonary complications were encountered in 40% patients. Hemorrhage 
was encountered in 30% patients. Reflux was noted in 20% patients and 
could be managed conservatively.  
 
Complication  
 
Mortality  1 (10%) 
Pulmonary complications 4 (40%) 
Haemorrhage 3 (3%) 
Reflux 2 (20%) 
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DISCUSSION 
 In this study, on analysis of the cases of carcinoma esophagus admitted 
at GRH it was seen that the disease is more prevalent among the males. (M:F-
3.5:1) which is similar to the incidence in western countries. (In the U.S. M.F. – 
4:1) (Ref 1). 
 The peak age of incidence was the sixth decade followed next by the 5th 
decade which is similar to the incidence world wide (Ref 2) 
 On analyzing the symptoms at presentation it was seen that Dysphagia 
was the most common presenting symptom (94%) along with weight loss and 
anorexia (70%). This correlates cell with international statistics (Ref 3) 
Symptoms of Ca esophagus and cardia (Ref-3) 
Dysphagia 85.4% 
Weight loss 60.9% 
Pain 26.5% 
Regurgitation 22.8% 
Hoarseness 4.4% 
Cough 2.5% 
 (N = 907) 
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 The commonest site of incidence was the mid third 50% of the 
esophagus in this study followed by lower third (which includes OG junction 
growth) 33% upper third tumours were least common 17%. This differs from 
western literature where the reported commonest site of incidence is the lower 
third making up 55% of the total tumors, followed only by mid third which 
make up 37%. Upper third tumours were rare (9%) (Ref 4,5,6). 
Adenocarcinomas of the esophagus and cardia are relatively common in 
the Western hemisphere. The reported incidence of these cancers is increasing 
in the United States at a rate surpassing that of any other cancer. However 
Squamous cell carcinomas are the most common histological type of carcinoma 
esophagus worldwide (Ref. 7,8,9,10). In this study, Squamous cell carcinoma 
was the predominant histology forming 89% of the tumors. The remaining 11% 
weree Adenocarcinomas. 
Presentation with carcinoma oesophagus was late in this study, majority 
presenting with either locally advanced or metastatic disease (80%). This 
correlates well but is higher than in western studies where the presentation with 
advanced disease varied from 60 – 75%( Ref. 9,10,11,12). 
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CONCLUSION 
1. Incidence of Carcinoma esophagus is more common in males 
2. Maximum incidence is in the 6th decade followed by the 5th decade. 
3. Dysphagia and weight loss are the most common but late presenting 
features 
4. Most common site of presentation is in the middle third in our 
population 
5. Squamous cell Carcinoma still remains the predominant 
histological variety in our population. 
6. Carcinoma esophagus has an aggressive behaviours and usually 
presents in late stages with a low rate of respectability. 
7. Even with incurable disease, resection can offer superior palliation 
with restoration of swallowing. 
8. Transhiatal resection offers comparable results to transthoracic 
resection with lower operative risk. 
TRANSHIATAL ESOPHAGECTOMY 
AFTER STOMACH MOBILISATION & ESOPHAGEAL 
 RESECTION 
 
GASTRIC TUBE FASHIONING 
 
GASTRIC TUBE 
 
TRANSHIATAL ESOPHAGECTOMY 
 
CERVICAL ESOPHAGO – GASTIC ANASTOMOSIS 
 
 
CERVICAL WOUND 
 
 
POST OF SPECIMENS 
 
 
ENDOSCOPIC VEIW OF BARRETS LESIONS 
           
 
ENDOSCOPIC VEIW OF EARLY CARCINOMA 
          
 
ENDOSCOPIC VEIW OF ADVANCED CARCINOMA  
   
PROFORMA 
 
NAME :     IP NO  : 
AGE :     UNIT  : 
SEX :     WARD : 
 
HISTORY 
Dysphagia 
odynophagia 
Regurgitation 
Respiratory infections 
GI bleed 
Weight loss ./ anorexia 
Cough and hoarseness 
other symptoms 
 
CLINCIAL EXAMINATION 
Jaundice 
Hepatomegaly 
Ascites 
Axillary / Cervical nodes 
Others 
 
INVESTIGATIONS 
UGI Scopy 
Biopsy HPE 
Ul;trasound abdomen 
CT Chest & Abdomen 
Barium swallow 
Chest x – ray 
Other 
DIAGNOSIS 
STAGE  
SITE 
TREATMENT 
Surgery : 
 Resectional Surgery 
Palliative surgery 
Radiotherapy 
Chemotherapy 
Supprotive Care 
POST OP GOLLOW – UP   
Complication 
Management 
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